942 related articles for article (PubMed ID: 15688191)
21. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
22. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
23. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
Wang SX; Li H
Chin Med J (Engl); 2008 Jul; 121(14):1280-4. PubMed ID: 18713548
[TBL] [Abstract][Full Text] [Related]
24. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
25. Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK₂) in postmenopausal RA patients.
Suzuki K; Tsuji S; Fukushima Y; Nakase T; Hamada M; Tomita T; Yoshikawa H
Mod Rheumatol; 2013 May; 23(3):450-5. PubMed ID: 22692649
[TBL] [Abstract][Full Text] [Related]
26. Monitoring alendronate therapy for osteoporosis.
Braga de Castro Machado A; Hannon R; Eastell R
J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.
Kučukalić-Selimović E; Valjevac A; Hadžović-Džuvo A; Skopljak-Beganović A; Alimanovic-Alagić R; Brković A
Bosn J Basic Med Sci; 2011 Feb; 11(1):41-5. PubMed ID: 21342141
[TBL] [Abstract][Full Text] [Related]
28. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.
Tucci JR; Tonino RP; Emkey RD; Peverly CA; Kher U; Santora AC
Am J Med; 1996 Nov; 101(5):488-501. PubMed ID: 8948272
[TBL] [Abstract][Full Text] [Related]
29. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study.
Uchida K; Nakajima H; Miyazaki T; Yayama T; Kawahara H; Kobayashi S; Tsuchida T; Okazawa H; Fujibayashi Y; Baba H
J Nucl Med; 2009 Nov; 50(11):1808-14. PubMed ID: 19837766
[TBL] [Abstract][Full Text] [Related]
30. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.
Meier C; Woitge HW; Witte K; Lemmer B; Seibel MJ
J Bone Miner Res; 2004 Aug; 19(8):1221-30. PubMed ID: 15231008
[TBL] [Abstract][Full Text] [Related]
31. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
32. Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.
Gonnelli S; Cepollaro C; Montomoli M; Gennari L; Montagnani A; Palmieri R; Gennari C
Clin Endocrinol (Oxf); 1997 Jan; 46(1):55-61. PubMed ID: 9059558
[TBL] [Abstract][Full Text] [Related]
33. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
Rhee Y; Kang M; Min Y; Byun D; Chung Y; Ahn C; Baek K; Mok J; Kim D; Kim D; Kim H; Kim Y; Myoung S; Kim D; Lim SK
Osteoporos Int; 2006 Dec; 17(12):1801-7. PubMed ID: 17019520
[TBL] [Abstract][Full Text] [Related]
34. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy.
Fujita T; Satomura A; Hidaka M; Ohsawa I; Endo M; Ohi H
Calcif Tissue Int; 2000 Mar; 66(3):195-9. PubMed ID: 10666494
[TBL] [Abstract][Full Text] [Related]
35. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
Holloway L; Kohlmeier L; Kent K; Marcus R
J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Tan W; Sun J; Zhou L; Li Y; Wu X
J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
[TBL] [Abstract][Full Text] [Related]
37. Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis.
Dursun N; Dursun E; Yalçin S
Int J Clin Pract; 2001 Oct; 55(8):505-9. PubMed ID: 11695068
[TBL] [Abstract][Full Text] [Related]
38. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
Tiraş MB; Noyan V; Yildiz A; Biberoğlu K
Climacteric; 2000 Jun; 3(2):92-101. PubMed ID: 11910657
[TBL] [Abstract][Full Text] [Related]
39. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.
Jensen TW; Hansen MS; Hørslev-Petersen K; Hyldstrup L; Abrahamsen B; Langdahl B; Zerahn B; Pødenphant J; Stengaard-Petersen K; Junker P; Østergaard M; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen AJ; Tarp U; Lindegaard H; Jurik AG; Vestergaard A; Hetland ML;
Ann Rheum Dis; 2014 Jun; 73(6):1123-9. PubMed ID: 23661492
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.
Yan Y; Wang W; Zhu H; Li M; Liu J; Luo B; Xie H; Zhang G; Li F
J Bone Miner Metab; 2009; 27(4):471-8. PubMed ID: 19343272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
